Experienced Corporate Director & CEO To Help Guide Aseptic Fill & Finish Startup
Salubrent Pharma Services, a newly created CDMO offering flexible state-of-the-art aseptic fill & finish and related analytical and development services, has announced that pharma industry veteran Doug Drysdale has joined their Board of Directors. Drysdale is currently the CEO of Cybin, a life sciences company advancing psychedelic pharmaceuticals.
In his career, Drysdale has chaired the Board of a NASDAQ-listed company and, as CEO for the past 13 years, has built and revitalized four pharmaceutical companies. During his thirty years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed fifteen corporate acquisitions across three continents and has raised $4 billion of both public and private capital.
In 2008, Drysdale led the turnaround of Norwich Pharmaceuticals and became the Founding CEO of parent company, Alvogen. In early 2014, he led the recapitalization of NASDAQ-listed Pernix Therapeutics, ultimately raising $465 million of capital. From late 2017 to mid-2020, Doug was Director and CEO of Tedor Pharma, a contract manufacturing business, where his efforts led to Tedor being recognized as one of America’s fastest-growing companies, making it to the 2020 Inc 5000 list.
“Salubrent is an exciting company pioneering true innovations in the fill & finish space,” Doug Drysdale commented. “Between their inventive approach, their incredibly talented team, and their solid growth roadmap, I predict great things for this company. I’m honored to be a part of their journey.”
“Doug is an amazing corporate director and CEO, brimming with insights into the future of the pharma industry,” added Terry Novak, Salubrent’s Chairman & CEO. “We’re incredibly excited for him to join our Board and help us create the future of fill & finish development and manufacturing.”
ABOUT SALUBRENT PHARMA SERVICES
Salubrent Pharma Solutions is a full-service CDMO offering analytical services to clinical and commercial stage pharma and biotech companies. Founded by industry veterans with over 200 years of combined industry experience, Salubrent provides clinical and commercial stage pharma and biotech companies with the expertise needed to successfully bring their products to the clinic and eventually the market. Salubrent will soon begin construction on the first of four US-based aseptic fill-finish facilities, each located in a major biotech hub and focusing on personalized medicine and PI/II CTM batches for those companies in need of small batch production of sterile injectable products.. Analytical services will be available in 2021, with proof-of-concept commercial aseptic services launching in 2022.
Learn more at salubrent.com